Key information made simple
This summary needs review. Please check the official study record and contact the research team for details.
CompletedNCT00154258
A Long Term Study of Clozapine in people with Treatment-resistant Schizophrenia
This study is completed. It focuses on schizophrenia and currently lists study information.
SchizophreniaDrugFrom 18 Years to 64 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
Check the study details
Check the official source, then confirm these points with the research team.
View official study record (opens in a new tab)
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateApril 2001
- Recruitment status
- Completed
- Enrollment listed in the registry
- 19
- Sponsor
- Novartis
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Not clearly listed
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT00154258
- Official title
- An Open Extension Study to Phase IIb Study of Clozapine in Patients With Treatment-resistant Schizophrenia
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT00154258. We help you review the study, but cannot decide medical eligibility.
Recruitment & locations
CompletedLocations not listed
Questions about this study
Who is behind this study?
The study sponsor is Novartis.
Does this study involve medication?
Yes. The study involves medication, including Clozapine.
Who can participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 64 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as completed.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT01157351
15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
This study is completed. It focuses on schizophrenia and currently lists study information in the United States.
CompletedNCT00818298
24-Hour Time Course of Striatal Dopamine D2 Receptor Occupancy of Ziprasidone: A PET Study
This study is completed. It focuses on schizophrenia and currently lists study information in Canada.
CompletedNCT00752427
Flexible Doses of Extended Release OROS® Paliperidone for schizophrenia
This study is completed. It is testing Flexible Doses of Extended Release OROS® Paliperidone for schizophrenia.